To evaluate the local oncologic effectiveness of image guided thermal ablation of recurrent renal cell carcinoma (RCC) after ipsilateral partial nephrectomy METHODS: We reviewed our institutional database for patients who underwent renal ablation for local recurrence in the ipsilateral kidney following partial nephrectomy between January 2005 and December 2017. We described demographics, tumor size, procedure details, complications, pathology and local oncologic outcome on follow up imaging.
INTRODUCTION AND OBJECTIVES:
To evaluate the local oncologic effectiveness of image guided thermal ablation of recurrent renal cell carcinoma (RCC) after ipsilateral partial nephrectomy METHODS: We reviewed our institutional database for patients who underwent renal ablation for local recurrence in the ipsilateral kidney following partial nephrectomy between January 2005 and December 2017. We described demographics, tumor size, procedure details, complications, pathology and local oncologic outcome on follow up imaging.
RESULTS: Out of 525 renal ablations during the study period, a total of 33 patients (19 Males and 14 females) with a median age of 66 years met our inclusion criteria. Fifteen patients had a solitary kidney. Forty-two procedures were performed for 46 lesions with average size of 2.3 cm (range 0.8-4.5 cm). Four lesions were at the surgical margin. Pathology report revealed negative tumor margin in 3 patients, the fourth patient had surgery at another institution with no pathology report available. Of the 42 procedures, 38 were performed under CT and 4 were performed under MRI guidance. Of the 46 lesions, 38 were treated with RFA and 8 were treated with cryoablation. Technical success was obtained in all cases. Adjunctive Techniques; hydrodissection and pyeloperfusion were performed in 11 and 2 cases respectively. Four patients (12 %) developed Clavien Grade III complications. Of the 37 biopsied lesions, 33 samples were diagnostic (20 clear cell and 13 papillary). Fuhrman grading was obtained in 27 lesions (Grade 1 [ 2, Grade II [ 21, Grade III [ 4) . Median follow up imaging was 4 years (0.9-11.5 years).Three lesions (6.5%) had residual/recurrence at the ablation site detected at 5.7, 6.6 and 7.3 months after ablation CONCLUSIONS: Thermal ablation is effective in treatment of recurrent RCC after ipsilateral partial nephrectomy. Long term follow imaging reveals favorable oncologic outcome in those patients is the primary treatment modality for cT1 renal masses, yet high quality data comparing PN and thermal ablation is lacking. We sought to review and update our experience with PN, percutaneous radiofrequency ablation (RFA), and percutaneous cryoablation for cT1 renal masses with additional follow up.
METHODS: We identified 1,798 patients with primary cT1N0M0 renal masses treated between 2000 and 2011 from the prospectively maintained Mayo Clinic Renal Tumor Registry. Local recurrence-free, metastases-free, and cancer-specific survival were estimated using the Kaplan-Meier method and compared with log-rank tests.
RESULTS: Among 1422 cT1a patients, 1055, 180, and 187 underwent PN, RFA, and cryoablation, respectively. Median clinical follow-up for survivors was 9.4, 7.5, and 6.3 years for PN, RFA, and cryoablation patients, respectively during which time local recurrencefree (p[0.29), metastases-free, (p[0.18), and cancer-specific survival (p[0.19) were comparable among the three treatments.
Among 376 cT1b patients, 324 underwent PN and 52 were managed with cryoablation. Median clinical follow-up for survivors was 8.7 and 6.0 years for PN and cryoablation patients, respectively, during which time local recurrence-free (p[0.47),metastases-free (p[0.94), and cancer-specific survival (p[0.13) were comparable between PN and cryoablation. Limitations include retrospective review and selection bias.
CONCLUSIONS: In this large cohort, single institution experience with long-term follow up, we report similar local recurrence-free, metastases-free and cancer specific survival for partial nephrectomy and thermal ablation treatment modalities for cT1 renal masses. Overall survival remained superior after PN, although is likely attributable to selection bias. These results further support recently updated guidelines.
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PD51-04 TEN-YEAR EXPERIENCE WITH PERCUTANEOUS CRYOABLATION OF RENAL TUMORS: TUMOR SIZE PREDICTS TREATMENT FAILURE
Nicholas Pickersgill*, Joel Vetter, Eric Kim, Kefu Du, Ramakrishna Venkatesh, Sam Bhayani, Robert Figenshau, Saint Louis, MO INTRODUCTION AND OBJECTIVES: Percutaneous cryoablation (PCA) has emerged as a promising alternative to extirpative management of renal tumors in selected patients, with a reduced risk of perioperative complications. Disease recurrence is thought to occur most commonly in the early post-operative period. However, long-term oncologic follow-up data is lacking. We reviewed our ten-year institutional experience with PCA for renal tumors and assessed predictors of treatment failure.
METHODS: We examined our prospectively maintained database of patients who underwent renal PCA from March 2005 to December 2015 (n[308) at a single institution. Baseline patient and tumor variables were recorded, and post-operative clinically-obtained cross-sectional imaging was examined for evidence of persistent or recurrent disease. Kaplan-Meier estimated survival curves were generated for disease-free survival (DFS) and Cox proportional hazards analysis was performed to identify predictors of DFS.
RESULTS: Mean patient age was 67.2þ11 years, mean tumor size was 2.7þ1.3 cm, and mean nephrometry score was 6.8þ1.7. At mean follow-up of 38 months, disease progression (e.g. new lymphadenopathy or metastasis) and/or local recurrence was observed in 14.3% (44/308) of patients. Excluding patients with solitary kidneys or Von Hippel Lindau syndrome, disease progression and/or local recurrence was observed in 10.1% (27/241) of patients. Of those with local recurrence, 80.6% (25/31) underwent re-ablation. The Kaplan-Meier estimated DFS curve is displayed in Figure 1 . An initial plateau in treatment failures occurs approximately 24 months following PCA, followed by an equal number of treatment failures between 24 to 60 months. Controlling for age, body-mass-index, comorbidity, and tumor location, tumor size and comorbidity with chronic obstructive pulmonary disease (COPD) were significant predictors of treatment failure (HR 1.33 per 1 cm increase in size, p [0.001; HR 3.04, p[0.02, respectively) .
CONCLUSIONS: In our ten-year institutional experience with PCA for the management of renal tumors, treatment failure occurs in approximately 10% of cases. Of these, roughly half occur beyond 24 months post-operatively. Increasing tumor size and comorbidity with COPD are both significant predictors of treatment failure.
